Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Submission of Matters to a Vote of Security Holders

0

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07.

Submission of Matters to a Vote of Security
Holders.

Karyopharm Therapeutics Inc. (the Company) held its 2017 Annual
Meeting of Stockholders on June15, 2017. The following is a
summary of the matters voted on at that meeting.

1. The Companys stockholders elected J. Scott Garland, Barry E.
Greene and Mansoor Raza Mirza, M.D. as class I directors to
serve until the 2020 Annual Meeting of Stockholders, each
such director to hold office until his successor has been
duly elected and qualified. The results of the stockholders
vote with respect to the election of such class I directors
were as follows:
Votes For VotesWithheld BrokerNon-Votes

J. Scott Garland

31,936,975 54,836 6,592,242

Barry E. Greene

31,931,294 60,517 6,592,242

Mansoor Raza Mirza, M.D.

31,550,182 441,629 6,592,242
2. The Companys stockholders ratified the selection of Ernst
Young LLP as the Companys independent registered public
accounting firm for the current fiscal year. The results of
the stockholders vote with respect to such ratification were
as follows:

VotesFor

VotesAgainst

VotesAbstaining

38,563,560

19,993


About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.